Overall patient characteristics
| No. of patients | 21 |
| Median age (y) | 38 |
| Range | 27-55 |
| Male/female | 10/11 |
| Diagnosis | |
| AML | 3 |
| ALL | 5 |
| CML | 10 |
| Others | 3 |
| Conditioning regimen | |
| CY/fTBI | 19 |
| BU/CY | 2 |
| GVHD prophylaxis | |
| CSA/MTX | 20 |
| CSA | 1 |
| SC donors | |
| Serologic and LBT match | 17 |
| Serologic class I mismatch | 4 |
| Related/unrelated | 6/15 |
| SC source | |
| BM | 19 |
| PBSC | 2 |
| No. of patients | 21 |
| Median age (y) | 38 |
| Range | 27-55 |
| Male/female | 10/11 |
| Diagnosis | |
| AML | 3 |
| ALL | 5 |
| CML | 10 |
| Others | 3 |
| Conditioning regimen | |
| CY/fTBI | 19 |
| BU/CY | 2 |
| GVHD prophylaxis | |
| CSA/MTX | 20 |
| CSA | 1 |
| SC donors | |
| Serologic and LBT match | 17 |
| Serologic class I mismatch | 4 |
| Related/unrelated | 6/15 |
| SC source | |
| BM | 19 |
| PBSC | 2 |
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; CY, cyclophosphamide; fTBI, fractionated total body irradiation; BU, busulfan; GVHD, graft-versus-host disease; CSA, cyclosporine; MTX, methotrexate; SC, stem cell; LBT, ligation-based typing of class II; BM, bone marrow; PBSC, peripheral blood stem cells.